New Stock Issuance - ST凯利 (300326) is undergoing a tender offer from July 17, 2025, to August 15, 2025[1] - 中程退 (300208) has its last trading day on July 18, 2025[1] - 退市锦港 (600190) and 退市锦B (900952) also have their last trading day on July 18, 2025[1] Market Alerts - 广生堂 (300436) is experiencing severe abnormal fluctuations as of July 17, 2025[1] - 华银电力 (600744) has a market alert issued on July 15, 2025[1] - 扬电科技 (301012) and 新易盛 (300502) have announcements made on July 17, 2025[1] Other Notable Stocks - 皇氏集团 (002329) and 浙江黎明 (603048) have announcements on July 18, 2025[1] - ST立方 (300344) and 国晟科技 (603778) also have announcements on July 18, 2025[1] - 英利汽车 (601279) and 天宸股份 (600620) have announcements on July 18, 2025[1]

New Stock Listings - Huadian New Energy (600930) listed at an issue price of 3.18 on July 16, 2025[1] - Zhongcheng Tui (300208) has 2 trading days remaining until the last trading day[1] - Tui Shi Jin Gang (600190) also has 2 trading days remaining until the last trading day[1] Abnormal Fluctuations - Huayin Power (600744) reported severe abnormal fluctuations on July 15, 2025[1] - Changcheng Military Industry (601606) announced abnormal fluctuations on July 15, 2025[1] - ST Yanzhen (603389) reported abnormal fluctuations on July 16, 2025[1] Other Notable Announcements - ST Ya Zhen (000627) reported significant fluctuations with a value of 7189 on July 16, 2025[3] - Guosheng Technology (603778) reported fluctuations with a value of 3370 on July 15, 2025[3] - ST Xin Chao (600777) reported fluctuations with a value of 1008 on July 11, 2025[3]

Core Points - The company announced an adjustment to the conversion price of its convertible bonds due to the implementation of the 2024 annual profit distribution [1][3] - The conversion price will be adjusted from 13.00 CNY per share to 12.97 CNY per share, effective from July 18, 2025 [1][4] - The convertible bonds, known as "润达转债," were issued in June 2020 with a total amount of 550 million CNY and a maturity of six years [1][2] Summary by Sections 1. Securities Suspension and Resumption - The "润达转债" will be suspended from conversion from July 10, 2025, to July 17, 2025, and will resume conversion on July 18, 2025 [1][4] 2. Conversion Price Adjustments - The conversion price has been adjusted multiple times in the past due to annual profit distributions, with the latest adjustment being from 13.00 CNY to 12.97 CNY [2][3] - The adjustment formula for the conversion price is based on the distribution of cash dividends and other equity changes [4] 3. Dividend Distribution - The company will distribute a cash dividend of 0.30 CNY per 10 shares, which is included in the conversion price adjustment [3][4]

Group 1 - The company's主体信用等级 is maintained at "AA" with a stable rating outlook [1][2] - The credit ratings for the issued "润达转债" and "23 润达医疗 MTN001" are also maintained at "AA" [1][2] - The credit rating agency, 新世纪评估, conducted a comprehensive analysis of the company's industry and operational status before confirming the ratings [2]

Core Viewpoint - The company, Shanghai RunDa Medical Technology Co., Ltd., is positioned well in the in-vitro diagnostic (IVD) market, benefiting from strong demand driven by economic growth, aging population, and upgrading medical consumption structure [1][3][6]. Company Overview - RunDa Medical focuses on the IVD sector, establishing a nationwide business layout and accumulating a significant customer and supplier base [1][3]. - The company has introduced state-owned capital as a controlling shareholder, enhancing its financial channels and collaboration with public healthcare institutions [3][6]. Market Environment - The IVD market is characterized by strong demand due to factors such as economic growth, an aging population, and increased healthcare spending [6][8]. - The industry faces challenges from regulatory changes and intense competition, which may impact revenue and profitability [3][6][8]. Financial Performance - The company's revenue has shown a decline, with total revenue for 2024 at 83.06 billion, down from 91.40 billion in 2023, reflecting a 9.13% decrease [8][9]. - The gross profit margin has also decreased, with a comprehensive gross margin of 25.37% in 2024 compared to 26.58% in 2023 [8][9]. Business Operations - RunDa Medical operates two main business segments: commercial comprehensive services and industrial services, with the commercial segment contributing over 90% of total revenue [10][12]. - The company has expanded its service offerings to include AI medical solutions, collaborating with major hospitals and healthcare institutions [9][10]. Competitive Position - The company has established a robust supply chain with over 1,200 suppliers and nearly 19,000 product varieties, ensuring comprehensive coverage of the IVD market [19][20]. - RunDa Medical's focus on R&D in IVD products and digital solutions positions it competitively within the industry [20]. Future Outlook - The company anticipates stable credit quality in the coming months, although potential downgrades may occur due to significant performance deterioration or changes in major stakeholders [3][4]. - Continued investment in AI and digital health solutions is expected to enhance market competitiveness and operational efficiency [9][10].

Group 1 - The company has returned all idle raised funds amounting to 180 million yuan to its special account for raised funds, as approved by the board of directors [1][2] - The funds were temporarily used to supplement the company's liquidity for a period not exceeding 12 months [1] - The company has notified the sponsor institution, Guojin Securities Co., Ltd., regarding the return of the funds [1] Group 2 - The company will begin paying interest on its convertible bonds, "Run Da Convertible Bonds," starting from June 17, 2025, for the period from June 17, 2024, to June 16, 2025 [3][4] - The interest payment amount for each bond with a face value of 100 yuan will be 1.80 yuan (including tax) [11][14] - The bond's interest rate for the fifth year is set at 1.8% [11][14] Group 3 - The bond's record date for interest payment is June 16, 2025, and the ex-dividend date is June 17, 2025 [5][15] - The total issuance scale of the convertible bonds is 550 million yuan, with a total of 5.5 million bonds issued [6] - The initial conversion price of the bonds has been adjusted to 13.00 yuan per share as of July 19, 2024, due to profit distribution [10]

Group 1 - The China Securities Convertible Bond Index opened flat [1] - Jiuzhou Convertible Bond 2 increased by over 3% [1] - Runda Convertible Bond rose by over 2% [1] Group 2 - Henghui Convertible Bond declined by over 1% [1] - Yitian Convertible Bond and Outong Convertible Bond fell nearly 1% [1]

Core Viewpoint - The company has decided not to exercise the early redemption rights for its convertible bonds, despite meeting the conditions for redemption, to protect investor interests and due to existing financial commitments [2][6]. Group 1: Convertible Bond Redemption - The company's stock has met the condition of having at least 15 trading days with closing prices not lower than 130% of the current conversion price over a 30-day period from April 29, 2025, to May 22, 2025, triggering the redemption clause for the "Run Da Convertible Bonds" [2][5]. - The board of directors unanimously agreed not to redeem the "Run Da Convertible Bonds" early during a meeting held on May 22, 2025, considering current market conditions and financial arrangements [6][7]. - The company will not exercise the early redemption rights for the next three months, from May 23, 2025, to August 22, 2025, even if the redemption conditions are met again [2][6]. Group 2: Convertible Bond Issuance Overview - The company issued 5,500,000 convertible bonds on June 17, 2020, with a total amount of 55 million yuan and a maturity of six years, with varying interest rates from 0.3% to 2.0% over the term [3][4]. - The initial conversion price was set at 13.36 yuan per share, which has been adjusted multiple times due to profit distributions, currently standing at 13.10 yuan per share as of July 18, 2023 [3][4]. Group 3: Related Party Transactions - The company's actual controllers, major shareholders, and senior management have not held "Run Da Convertible Bonds" in the six months prior to the redemption conditions being met and have no plans to reduce their holdings in the next six months [7].